IdorsiaXSWX:IDIA -0.30%48 Return-on-Tangible-Asset is -41.24% as of Mar. 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Idorsia ranks worse than 59.63% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Idorsia's annualizedNet Income for the quarter that ended in Mar. 2026 was CHF-182.8 Mil. Idorsia's average total tangible assets for the quarter that ended in Mar. 2026 was CHF443.2 Mil. Therefore, Idorsia's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -41.24%.
The historical rank and industry rank for Idorsia's Return-on-Tangible-Asset or its related term are showing as below:
XSWX:IDIA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -69.98 Med: -38.82 Max: -1.29
Current: -50.04
During the past 10 years, Idorsia's highest Return-on-Tangible-Asset was -1.29%. The lowest was -69.98%. And the median was -38.82%.
XSWX:IDIA's Return-on-Tangible-Asset is ranked worse than 59.63% of 1412
companies
in the Biotechnology industry
Industry Median: -35.66
vs XSWX:IDIA: -50.04
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Idorsia Return-on-Tangible-Asset Related Terms
Idorsia Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Idorsia's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Idorsia's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Idorsia's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -41.24% mean?
Idorsia (XSWX:IDIA) has a Return-on-Tangible-Asset of -41.24% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #842 out of 1412 companies in the Biotechnology industry, placing it in the top 59.6%.
Is Idorsia's Return-on-Tangible-Asset too high?
Idorsia's current Return-on-Tangible-Asset is -41.24%. Based on the distribution chart, Idorsia ranks #842 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #842 out of 1412 companies for Return-on-Tangible-Asset. This places Idorsia in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Idorsia and its competitors. Idorsia's current Return-on-Tangible-Asset is -41.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.87, compared to a current price of CHF6.55 — trading 128.2% above its estimated fair value. The current Return-on-Tangible-Asset is -41.24%. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Return-on-Tangible-Asset is -41.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.55 is trading 128.2% above its estimated GF Value™ of CHF2.87.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
Return-on-Tangible-Asset: -41.24%
GF Value™: CHF2.87 vs. price of CHF6.55 (128.2% above fair value)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
